From the publishers of JADPRO
CAR T-Cell Therapy
Resource Center
Menu
Resources
Videos
Videos
Fast Facts
Quizzes
News & Literature Highlights
Case Studies
Advertisement
Test your knowledge on ICANS management in patients receiving CAR T-cell therapy
Last Updated: Friday, April 7, 2023
Loading...
Advertisement
News & Literature Highlights
Transplantation and Cellular Therapy
Best practice considerations by the American Society of Transplant and Cellular Therapy: Infection prevention and management after chimeric antigen receptor T cell therapy for hematological malignancies
Blood Advances
CAR T-cell toxicities: From bedside to bench, how novel toxicities inform laboratory investigations
The New England Journal of Medicine
Obecabtagene autoleucel in adults with B-cell acute lymphoblastic leukemia
Immunotherapy
The potential of phytomedicines to optimize CAR-T cell therapy in cancer
Frontiers in Immunology
CAR-T cell therapy clinical trials: Global progress, challenges, and future directions from ClinicalTrials.gov insights
The Lancet
In-vivo B-cell maturation antigen CAR T-cell therapy for relapsed or refractory multiple myeloma
Blood
Intrathecal chemotherapy as treatment for chimeric antigen receptor T cell (CAR T) therapy associated neurotoxicity
Transplantation and Cellular Therapy
Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome
Future Oncology
Establishing a successful outpatient CAR T-cell program with cilta-cel: Real-world experience from an expert roundtable
Blood
Clinical features, pathophysiology, and management of acute myelopathy following CAR T-cell therapy
Advertisement
Case Studies
Navigating Treatment Adherence in Early-Stage Breast Cancer
Hemophagocytic Lymphohistiocytosis Following CAR T-Cell Therapy in a Patient With Multiple Myeloma
Bloodless Medicine Management of a Patient Receiving CAR T-Cell Therapy
Fast Facts
Fast Facts #12: BCMA Targets
Advertisement
Quizzes
How much have you learned this year?
Test your knowledge of hemophagocytic lymphohistiocytosis following CAR T-cell therapy in a patient with multiple myeloma
Test your knowledge of bloodless medicine management of a patient receiving CAR T-cell therapy